Effects of oral iron chelator deferasirox on human malignant lymphoma cells

Jong Gwon Choi, Jung Lim Kim, Joohee Park, Soonwook Lee, Seh Jong Park, Jun Suk Kim, Chul Won Choi

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: Iron is essential for cell proliferation and viability. It has been reported that iron depletion by a chelator inhibits proliferation of some cancer cells. Deferasirox is a new oral iron chelator, and a few reports have described its effects on lymphoma cells. The goal of this study was to determine the anticancer effects of deferasirox in malignant lymphoma cell lines. Methods: Three human malignant lymphoma cell lines (NCI H28:N78, Ramos, and Jiyoye) were treated with deferasirox at final concentrations of 20, 50, or 100 μM. Cell proliferation was evaluated by an MTT assay, and cell cycle and apoptosis were analyzed by flow cytometry. Western blot analysis was performed to determine the relative activity of various apoptotic pathways. The role of caspase in deferasirox-induced apoptosis was investigated using a luminescent assay. Results: The MTT assay showed that deferasirox had dose-dependent cytotoxic effects on all 3 cell lines. Cell cycle analysis showed that the sub-G1 portion increased in all 3 cell lines as the concentration of deferasirox increased. Early apoptosis was also confirmed in the treated cells by Annexin V and PI staining. Western blotting showed an increase in the cleavage of PARP, caspase 3/7, and caspase 9 in deferasirox-treated groups. Conclusion: We demonstrated that deferasirox, a new oral iron-chelating agent, induced early apoptosis in human malignant lymphoma cells, and this apoptotic effect is dependent on the caspase-3/caspase-9 pathway.

Original languageEnglish
Pages (from-to)194-201
Number of pages8
JournalKorean Journal of Hematology
Volume47
Issue number3
DOIs
Publication statusPublished - 2012 Dec 1

Fingerprint

Chelating Agents
Lymphoma
Iron
Apoptosis
Cell Line
Caspase 9
Caspase 3
Cell Cycle
Western Blotting
Cell Proliferation
Iron Chelating Agents
Luminescent Measurements
Caspase 7
deferasirox
Annexin A5
Caspases
Cell Survival
Flow Cytometry
Staining and Labeling
Neoplasms

Keywords

  • Apoptosis
  • Deferasirox
  • Malignant lymphoma

ASJC Scopus subject areas

  • Hematology

Cite this

Effects of oral iron chelator deferasirox on human malignant lymphoma cells. / Choi, Jong Gwon; Kim, Jung Lim; Park, Joohee; Lee, Soonwook; Park, Seh Jong; Kim, Jun Suk; Choi, Chul Won.

In: Korean Journal of Hematology, Vol. 47, No. 3, 01.12.2012, p. 194-201.

Research output: Contribution to journalArticle

Choi, Jong Gwon ; Kim, Jung Lim ; Park, Joohee ; Lee, Soonwook ; Park, Seh Jong ; Kim, Jun Suk ; Choi, Chul Won. / Effects of oral iron chelator deferasirox on human malignant lymphoma cells. In: Korean Journal of Hematology. 2012 ; Vol. 47, No. 3. pp. 194-201.
@article{cc7f3069ef9d4a0685f7904fd2abb2b5,
title = "Effects of oral iron chelator deferasirox on human malignant lymphoma cells",
abstract = "Background: Iron is essential for cell proliferation and viability. It has been reported that iron depletion by a chelator inhibits proliferation of some cancer cells. Deferasirox is a new oral iron chelator, and a few reports have described its effects on lymphoma cells. The goal of this study was to determine the anticancer effects of deferasirox in malignant lymphoma cell lines. Methods: Three human malignant lymphoma cell lines (NCI H28:N78, Ramos, and Jiyoye) were treated with deferasirox at final concentrations of 20, 50, or 100 μM. Cell proliferation was evaluated by an MTT assay, and cell cycle and apoptosis were analyzed by flow cytometry. Western blot analysis was performed to determine the relative activity of various apoptotic pathways. The role of caspase in deferasirox-induced apoptosis was investigated using a luminescent assay. Results: The MTT assay showed that deferasirox had dose-dependent cytotoxic effects on all 3 cell lines. Cell cycle analysis showed that the sub-G1 portion increased in all 3 cell lines as the concentration of deferasirox increased. Early apoptosis was also confirmed in the treated cells by Annexin V and PI staining. Western blotting showed an increase in the cleavage of PARP, caspase 3/7, and caspase 9 in deferasirox-treated groups. Conclusion: We demonstrated that deferasirox, a new oral iron-chelating agent, induced early apoptosis in human malignant lymphoma cells, and this apoptotic effect is dependent on the caspase-3/caspase-9 pathway.",
keywords = "Apoptosis, Deferasirox, Malignant lymphoma",
author = "Choi, {Jong Gwon} and Kim, {Jung Lim} and Joohee Park and Soonwook Lee and Park, {Seh Jong} and Kim, {Jun Suk} and Choi, {Chul Won}",
year = "2012",
month = "12",
day = "1",
doi = "10.5045/kjh.2012.47.3.194",
language = "English",
volume = "47",
pages = "194--201",
journal = "Blood Research",
issn = "2287-979X",
publisher = "Korean Society of Hematology",
number = "3",

}

TY - JOUR

T1 - Effects of oral iron chelator deferasirox on human malignant lymphoma cells

AU - Choi, Jong Gwon

AU - Kim, Jung Lim

AU - Park, Joohee

AU - Lee, Soonwook

AU - Park, Seh Jong

AU - Kim, Jun Suk

AU - Choi, Chul Won

PY - 2012/12/1

Y1 - 2012/12/1

N2 - Background: Iron is essential for cell proliferation and viability. It has been reported that iron depletion by a chelator inhibits proliferation of some cancer cells. Deferasirox is a new oral iron chelator, and a few reports have described its effects on lymphoma cells. The goal of this study was to determine the anticancer effects of deferasirox in malignant lymphoma cell lines. Methods: Three human malignant lymphoma cell lines (NCI H28:N78, Ramos, and Jiyoye) were treated with deferasirox at final concentrations of 20, 50, or 100 μM. Cell proliferation was evaluated by an MTT assay, and cell cycle and apoptosis were analyzed by flow cytometry. Western blot analysis was performed to determine the relative activity of various apoptotic pathways. The role of caspase in deferasirox-induced apoptosis was investigated using a luminescent assay. Results: The MTT assay showed that deferasirox had dose-dependent cytotoxic effects on all 3 cell lines. Cell cycle analysis showed that the sub-G1 portion increased in all 3 cell lines as the concentration of deferasirox increased. Early apoptosis was also confirmed in the treated cells by Annexin V and PI staining. Western blotting showed an increase in the cleavage of PARP, caspase 3/7, and caspase 9 in deferasirox-treated groups. Conclusion: We demonstrated that deferasirox, a new oral iron-chelating agent, induced early apoptosis in human malignant lymphoma cells, and this apoptotic effect is dependent on the caspase-3/caspase-9 pathway.

AB - Background: Iron is essential for cell proliferation and viability. It has been reported that iron depletion by a chelator inhibits proliferation of some cancer cells. Deferasirox is a new oral iron chelator, and a few reports have described its effects on lymphoma cells. The goal of this study was to determine the anticancer effects of deferasirox in malignant lymphoma cell lines. Methods: Three human malignant lymphoma cell lines (NCI H28:N78, Ramos, and Jiyoye) were treated with deferasirox at final concentrations of 20, 50, or 100 μM. Cell proliferation was evaluated by an MTT assay, and cell cycle and apoptosis were analyzed by flow cytometry. Western blot analysis was performed to determine the relative activity of various apoptotic pathways. The role of caspase in deferasirox-induced apoptosis was investigated using a luminescent assay. Results: The MTT assay showed that deferasirox had dose-dependent cytotoxic effects on all 3 cell lines. Cell cycle analysis showed that the sub-G1 portion increased in all 3 cell lines as the concentration of deferasirox increased. Early apoptosis was also confirmed in the treated cells by Annexin V and PI staining. Western blotting showed an increase in the cleavage of PARP, caspase 3/7, and caspase 9 in deferasirox-treated groups. Conclusion: We demonstrated that deferasirox, a new oral iron-chelating agent, induced early apoptosis in human malignant lymphoma cells, and this apoptotic effect is dependent on the caspase-3/caspase-9 pathway.

KW - Apoptosis

KW - Deferasirox

KW - Malignant lymphoma

UR - http://www.scopus.com/inward/record.url?scp=84874077087&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874077087&partnerID=8YFLogxK

U2 - 10.5045/kjh.2012.47.3.194

DO - 10.5045/kjh.2012.47.3.194

M3 - Article

C2 - 23071474

AN - SCOPUS:84874077087

VL - 47

SP - 194

EP - 201

JO - Blood Research

JF - Blood Research

SN - 2287-979X

IS - 3

ER -